Abstracts tagged "osteoporosis"

Abstract Number: 2214 • 2019 ACR/ARP Annual Meeting
Assessment of Bone Quality by Trabecular Bone Score (TBS) in Systemic Lupus Erythematosus Patients
Andrea Casabella ¹, Sabrina Paolino ², Alberto Sulli³, Elisa Alessandri ⁴, Vanessa Smith ⁵, Barbara Ruaro ⁶, Carmen Pizzorni ² and Maurizio Cutolo ⁷, ¹1 Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genova, ⁵Dept. of Rheumatology, Ghent University Hospital, Ghent, Belgium; Dept. of Internal Medicine, Ghent University, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium, Gent, Belgium, ⁶1 Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 2 Cardinal Ferrari Centre, S. Stefano Rheabilitation, Fontanellato (Parma), Italy, Genoa, Italy, ⁷Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) patients show an increased risk of low bone mass as a result of multifactorial events: physical inactivity, persistent inflammation, low…
Abstract Number: 1333 • 2019 ACR/ARP Annual Meeting
The Comparative Risk of Osteoporotic Fractures Among Patients with Rheumatoid Arthritis Receiving TNF Inhibitors versus Other Biologics: A Nation-wide Cohort Study in Korea
Eun Hye Park¹, Anna Shin ², Yaa-Hui Dong ³, You-Jung Ha ¹, Yun Jong Lee ⁴, Eun Bong Lee ⁵, Yeong-Wook Song ⁶ and Eun Ha Kang ¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ²Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ³Graduate Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan (Republic of China), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul, ⁶Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of osteoporosis and osteoporotic fracture, but little is known about comparative risk of osteoporotic fractures between…
Abstract Number: 2215 • 2019 ACR/ARP Annual Meeting
Modeling-Based Bone Formation Persists in the Femoral Neck Despite Remodeling Inhibition in Subjects Treated with Denosumab
David Dempster¹, Peter Butler ², Mathias Bostrom ³, Jeri Nieves ¹, Hua Zhou ⁴, Li Chen ², Nicola Pannacciulli ², Rachel Wagman ² and Felicia Cosman ¹, ¹Columbia University, New York, NY, ²Amgen Inc., Thousand Oaks, CA, ³Hospital for Special Surgery, New York, NY, ⁴Helen Hayes Hospital, West Haverstraw, NY
Background/Purpose: Denosumab (DMAb) is a potent antiresorptive agent, but findings in non-human primates suggest that modeling-based bone formation (MBBF) may persist despite DMAb treatment (Ominsky…
Abstract Number: 1872 • 2019 ACR/ARP Annual Meeting
Worsening Trends in Osteoporosis Management in the Medicare Population: 2010-2014
Jeffrey Curtis¹, Shanette G. Daigle ², Setareh A. Williams ³, Richard Weiss ³, Yamei Wang ⁴ and Tarun Arora ², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³Radius Health, Inc, Waltham, ⁴Radius Health, Inc, Waltham
Background/Purpose: Osteoporotic fractures are an important public health burden, and with an increasing aging population, the number of Americans at risk of fractures is projected…
Abstract Number: 2216 • 2019 ACR/ARP Annual Meeting
Bone Mineral Density of the Spine, Hip, and Distal Radius in Patients with Postmenopausal Osteoporosis
KEN NAKASEKO¹, ¹Department of Orthopaedic Surgery and Rheumatology Kuwana City Medical Center, kuwana mie, Japan
Background/Purpose: Bone mineral density (BMD) is used for the diagnosis of osteoporosis, predicting future fracture risk, and monitoring osteoporosis treatment. Osteoporosis is defined as BMD…
Abstract Number: 1873 • 2019 ACR/ARP Annual Meeting
Geisinger HiROC Performance 2017-2018: Continuing to Narrow the Post-Fracture Treatment Gap
Thomas Olenginski¹ and Karen Mackiewicz ², ¹Geisinger Medical Center, Danville, PA, ²Geisinger, Danville, PA
Background/Purpose: The morbidity and mortality of osteoporotic fractures threaten our aging population. Despite advances in new therapies for osteoporosis and technology to more effectively communicate, fewer…
Abstract Number: 2217 • 2019 ACR/ARP Annual Meeting
DEXA Does Not Accurately Reflect FRAX Score in Patients with Autoimmune Disease on Corticosteroids
Sima Terebelo¹, Madina Abduraimova ¹, Latoya Freeman-Beman ¹, Naureen Kabani ², Joshy Pathiparampil ¹, Olga Dvorkina ² and Ellen M Ginzler ³, ¹SUNY Downstate Medical Center, Brooklyn, NY, ²SUNY Downstate Medical Center, Brooklyn, ³State University of New York Downstate Medical Center, Brooklyn, NY
Background/Purpose: Osteoporosis (OP) is a problem in the aging population. Patients with autoimmune disease are at increased risk for OP given their history of steroid…
Abstract Number: 1874 • 2019 ACR/ARP Annual Meeting
Extensive Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results from the FRAME Clinical Trial
Erik Eriksen¹, Roland Chapurlat ², Rogely Boyce ³, Jacques Brown ⁴, Stéphane Horlait ⁵, Cesar Libanati ⁶, Yifei Shi ³, Rachel Wagman ³ and Pascale Chavassieux ², ¹Department of Clinical Endocrinology, Oslo University Hospital and Institute of Clinical Medicine Oslo University, Oslo, Norway, ²INSERM UMR 1033, Université de Lyon, Lyon, France, ³Amgen Inc., Thousand Oaks, CA, ⁴CHU de Quebec Research Centre and Laval University, Quebec, QC, Canada, ⁵Amgen Inc., Boulogne Billancourt, France, ⁶UCB Pharma, Brussels, Belgium
Background/Purpose: The bone-forming agent romosozumab (Romo) is a monoclonal antibody that binds to/inhibits sclerostin, leading to increased bone formation and decreased bone resorption. The highest…
Abstract Number: 2219 • 2019 ACR/ARP Annual Meeting
Randomized Control Study in Glucocorticoid-Induced Osteoporosis Treated with Bisphosphonate or Denosumab (GOBID)
Ikuko Tanaka¹, Mari Ushikubo ², Misako Konishi ², Yutaro Hayashi ², Satoshi Hama ³, Keisuke Izumi ², Yutaka Okano ², Shigenori Tamaki ⁴ and Hisaji Ohshima ², ¹Nagoya Rheumatology Clinic, Ngoya, Japan, ²National Tokyo Medical Center, Tokyo, Japan, ³tokyo medical center, tokyo, Japan, ⁴Nagoya Rheumatology Clinic, Nagoya, Japan
Background/Purpose: It has not been established which therapy, bisphosphonates or denosumab, is more effective for glucocorticoid-induced osteoporosis (GIO). The purpose of this study was to…
Abstract Number: 1877 • 2019 ACR/ARP Annual Meeting
Romosozumab Improves Lumbar Spine Bone Mineral Density and Bone Strength Greater Than Alendronate as Assessed by Quantitative Computed Tomography and Finite Element Analysis in the ARCH Trial
Jacques Brown¹, Arkadi Chines ², Roland Chapurlat ³, Joseph Foldes ⁴, Xavier Nogues ⁵, Roberto Civitelli ⁶, Tobias De Villiers ⁷, Fabio Massari ⁸, Cristiano A. Zerbini ⁹, Wenjing Yang ², Chris Recknor ¹⁰ and Cesar Libanati ¹¹, ¹CHU de Quebec Research Centre and Laval University, Quebec, QC, Canada, ²Amgen Inc., Thousand Oaks, CA, ³INSERM UMR 1033, Université de Lyon, Lyon, France, ⁴Hadassah Hebrew University Medical Center, Jerusalem, Israel, ⁵IMIM Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain, ⁶Washington University School of Medicine, St. Louis, MO, ⁷Stellenbosch University, Stellenbosch, South Africa, ⁸Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, ⁹Centro Paulista de Investigação Clinica, São Paulo, Brazil, ¹⁰United Osteoporosis Centers, Gainesville, GA, ¹¹UCB Pharma, Brussels, Belgium
Background/Purpose: Recent evidence suggests BMD achieved during treatment is a reliable surrogate for fracture risk reduction (Bouxsein JBMR 2019). Romosozumab (Romo) is a bone-forming agent…
Abstract Number: 2220 • 2019 ACR/ARP Annual Meeting
Abaloparatide Followed by Alendronate on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis
Nancy Lane¹, Richard Weiss ², Bruce Mitlak ³, Yamei Wang ⁴, Guillermo Valenzuela ⁵ and Chad Deal ⁶, ¹University of California at Davis Medical Center, Sacramento, CA, ²Radius Health, Inc, Waltham, ³Radius Health, Inc, Waltham, MA, ⁴Radius Health, Inc, Waltham, ⁵Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁶Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Osteoporosis (OP) and osteoarthritis (OA) are often comorbid conditions in the elderly, with prevalence of OP in patients with OA reported as high as…
Abstract Number: 1929 • 2019 ACR/ARP Annual Meeting
Identification and Validation of Transcriptional Genes Associated with Osteoporotic Vertebral Fractures by Microarray Study, in Community Elderly Women
Levi Jales Neto¹, Zofia Wicik ², Georgea Torres ¹, Liliam Takayama ¹, Neusa Lopes ¹, alexandre Pereira ¹ and Rosa Pereira ³, ¹University of Sao Paulo, Sao Paulo, Brazil, ²University of Sao Paulo, São Paulo, Brazil, ³Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil
Background/Purpose: The pathogenesis of osteoporosis, a common disease with high morbidity1, comprises genetic and environmental factors2. Recent studies demonstrated that blood samples are a source…
Abstract Number: 2221 • 2019 ACR/ARP Annual Meeting
Bone Metabolism Impairment in Heart Transplant: Results from a Prospective Cohort Study
Luis Seguro ¹, Rosa Pereira ², Luciana Seguro³, Valeria Caparbo ³, Monica Avila ¹, Sandrigo Mangini ¹, Iascara Campos ¹, Fabio Gaiotto ¹, Fabiana Marcondes-Braga ¹ and Fernando Bacal ¹, ¹Instituto do Coracao (InCor), HCFMUSP, Sao Paulo, ²Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil, ³Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo
Background/Purpose: Data on prevention of fractures after heart transplant (HTx) are controversial in the literature. Understanding the effects of HTx on bone may guide appropriate…
Abstract Number: 1971 • 2019 ACR/ARP Annual Meeting
CD39 Produced from Human Gingiva-Derived Mesenchymal Stem Cells Regulates the Balance of Osteoclasts and Osteoblasts Through Wnt / β-catenin Pathway in Osteoporosis
Wenbin Wu¹, Julie Wang ², feng huang ¹, limin Rong ¹ and Song Guo Zheng ³, ¹Sun Yat-sen University, Guangzhou, ²Ohio State University, columbus, ³Ohio State College of Medicine, Columbus, OH
Background/Purpose: Osteoporosis led to severe bone-related diseases and increased mortality and health care costs. Existing treatments failed to reduce the risk of fractures in patients,…
Abstract Number: 2222 • 2019 ACR/ARP Annual Meeting
Bone Health: An Independent Predictor of Coronary Artery Disease
Lilian Bizzocchi¹, Maria Salgado ¹, Bhavin Chokshi ¹, Navneet Kaur ¹, Oscar Mena ¹ and Michal Packman ², ¹Jacobi Medical Center, Bronx, NY, ²North Central Bronx Hospital, Bronx, NY
Background/Purpose: An association between low bone mineral density (BMD) and cardiovascular events has been shown. The calcification process observed in atherosclerosis and bone mineralization have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].